Obrindatamab 产品活性：Obrindatamab 是一种人源化抗 B7-H3/CD3 双特异性抗体。Obrindatamab 结合 B7-H3 和 CD3，从而介导针对表达 B7-H3 的癌细胞的重定向细胞毒性 T 淋巴细胞 (CTL) 活性。Obrindatamab 可用于癌症研究。 产品来源： https://www.medchemexpress.cn/obrindatamab.html 研究领域：Immunology/Inflammation 作用靶点：CD3 In Vitro: MGD009 (MGD009) binds human and cynomolgus monkey CD3 and B7-H3 with KD values of 13.9, 14.7, 24.6, and 30.2 nM for human CD3ε/δ, cynomolgus CD3ε/δ, human B7-H3-His, and cynomolgus B7-H3-His, respectively. Obrindatamab (0.01-1000 ng/mL; A498, U87, 22Rv1, and Detroit562 cells) mediates redirected killing of multiple B7-H3-expressing tumor lines. Obrindatamab (0.01-1000 ng/mL; PBMCs and A498 cells) mediated T-cell activation and proliferation is target antigen dependent. In Vivo: Obrindatamab (MGD009; 0.004-1 mg/kg; i.v.) inhibits growth and tumor regression of B7-H3-expressing tumor xenografts in human T cell or PBMC-reconstituted mice. 相关产品：Teclistamab | Mosunetuzumab | Talquetamab | Epcoritamab | Solitomab | Muromonab | Teplizumab | Cibisatamab | Catumaxomab | Otelixizumab | Cevostamab | Gresonitamab | Pavurutamab | Nivatrotamab | Pacanalotamab | Pasotuxizumab | Voxalatamab | Anti-Mouse CD3 Antibody (17A2) | Foralumab | Linvoseltamab | Tepoditamab | Flotetuzumab | Plamotamab | Vepsitamab | Vibecotamab | Dafsolimab | Maydispenoid A | Maydispenoid B | Tidutamab | Ubamatamab 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。